Baseimmune secures funding for vaccine development
The investment, led by MSD Global Health Innovation Fund and IQ Capital, with contributions from Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc, will expedite the progress of
Biotechnology company PRISM BioLab has signed a target exclusive research and licensing agreement with Japan headquartered company ONO Pharmaceutical for jointly creating a development candidate for the latter’s oncology target.